·  Legal News, Analysis, & Commentary


Mylan Issues Urgent Recall for Insulin Pens

— January 20, 2022

Mylan Pharmaceuticals is recalling certain Semglee prefilled insulin injection pens because they may not be properly labeled.

Earlier this week, Mylan Pharmaceuticals made an urgent recall announcement for one batch of Semglee prefilled insulin injection pens because the pens are missing their labels. According to the notice, the recall includes pens in batch No. BF20003118. They expire on August 2022 and include “100 units/ml (U-100), 3mL prefilled pens in cartons of five.”

Image of a Warning Sign
Warning Sign; image courtesy of Peter-Lomas via Pixabay,

Though the cartons were all properly labeled, some of the pens are not. According to parent company Viatris, “in a diabetes patient taking more than one kind of insulin, this could lead to a mix-up of products/strengths, resulting in administration of the wrong insulin. Administration of the wrong insulin could result in less optimal glycemic control (either high or low blood sugar) which could result in serious complications.”

For now, Mylan is asking wholesalers and retailers to quarantine products from the batch. Customers who have the recalled pens should contact Stericycle for instructions on how to return the pens at 888-843-0255.

If you have questions or concerns about the recall, contact Viatris at or 800-796-9526. 


Insulin pens recalled for a problem that might lead to the wrong amount being injected

Mylan Pharmaceuticals Inc., a Viatris Company, Conducting Voluntary Recall of One Batch of Semglee® (insulin glargine injection), 100 units/mL (U-100), 3 mL Prefilled Pens, Due to the Potential for a Missing Label in the Batch

Join the conversation!